Active pharmaceutical ingredients (API) company MSN Labs, the parent company of Novadoz Pharmaceuticals, reported on Monday the receipt of US FDA approval to market Abiraterone Acetate 250mg tablets in 120 tablet count bottles for the treatment of prostate cancer with a steroid medication (prednisone or methylprednisolone).
This US FDA approval marks the ninth since March 2018, when Novadoz began commercial operations as MSN Labs' US sales and marketing affiliate for their finished dosage forms.The company expects additional product launches over the next 12 months continuing the organization's meteoric entrance and rise in the US market.
Additionally, the Abiraterone Acetate 250mg tablets is the second oncology product launched by Novadoz.
The company added that the Abiraterone Acetate 250mg tablets are the generic version of Janssen Pharmaceuticals' product Zytiga.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US